Skip to content Skip to footer
Subscribe Now
Viewpoint_Kai_Te_Kaat_2020
VIEWPOINTS
PharmaShots Interview: QIAGEN’s Kai te Kaat Shares Insights on QIAprep& Viral RNA UM Kit
In a recent interview with PharmaShots, Kai te Kaat, the Vice President, Head of Franchise Oncology, MDx at QIAGEN shares his insights and highlights on QIAprep& Viral RNA UM Kit. Shots: QIAGEN to launch the QIAprep& Viral RNA UM Kit, designed to simplify and accelerate PCR swab analysis and remove key testing bottlenecks for Covid-19 and other RNA viruses The…
October 19, 20200Comments
Viewpoint_Lotus Mallbris_2020
VIEWPOINTS
PharmaShots Interview: Eli Lilly’s Dr. Lotus Mallbris Shares Insights on Baricitinib
In a recent interview with PharmaShots, Dr. Lotus Mallbris, the Vice President of Immunology Development at Eli Lilly shares her insights and highlights on Baricitinib. Shots: If approved, Baricitinib could be the first JAK inhibitor in the EU for adults with moderate to severe AD. EC's decision is expected in the next one-two months. Lilly is evaluating Baricitinib for SLE, for which…
October 12, 20200Comments
Viewpoint_Dr. Neil Collinson_2020
VIEWPOINTS
PharmaShots Interview: Genentech’s Dr. Neil Collinson Shares Insights on Xofluza
In a recent interview with PharmaShots, Dr. Neil Collinson, the Senior Principal Clinical Development Scientist at Genentech / Roche shares his insights and highlights on Xofluza. Shots: The P-III BLOCKSTONE study demonstrated that the proportion of household members who became symptomatically ill following infection with influenza was significantly lower in those treated preventively with Xofluza…
September 22, 20200Comments